How to Start a GLP-1 Weight Loss Telehealth Business

GLP-1 weight management is the category that put telehealth on every founder's radar. Demand is real and durable. So is the competition, and so is the regulatory motion. If you are planning a GLP-1 telehealth business, here is the honest checklist: the two prescribing pathways, what changed in compounding, the clinical and compliance layers, and how a new brand actually competes.

Start with an honest read of the market

This is one of the most crowded categories in consumer health. Public companies, well-funded startups, and thousands of smaller brands are all bidding on the same searches and audiences, which makes GLP-1 keywords some of the most expensive advertising inventory in the space. Brands competing head-on in that auction commonly describe patient acquisition costs running into the hundreds of dollars. We break down the economics in patient acquisition cost for HRT vs GLP.

None of that means the category is closed. It means a GLP-1 brand needs a plan beyond "launch and buy ads." The founders who do well treat weight management as one door into a broader care relationship, and they build the infrastructure to support that from day one.

Before you build anything, decide three things. Who is your patient, specifically, and what is she or he struggling with beyond the scale? Which pathways will your catalog carry, knowing that one of them can narrow with little notice? And what will keep a patient with your brand after the first few months, once the novelty of starting care has worn off? Your answers shape the brand, the intake, the catalog, and the marketing.

The two pathways

Brand-name GLP-1 medications are the FDA-approved products patients ask for by name. They move through standard pharmacy channels and manufacturer programs. Patients trust the names, and the pathway is regulatory settled ground, though margins tend to be thinner.

Compounded GLP-1 medications are prepared by licensed 503A pharmacies or 503B outsourcing facilities, where the law allows it, and prescribed only when a licensed provider judges them clinically appropriate for the individual patient. Compounding is a legal pathway, but a compounded medication is not FDA approved, and it is never accurate to call it "generic." The full side-by-side lives in our explainer on compounded vs brand-name GLP-1, so we will not repeat it here.

Which pathway a given patient receives is a clinical decision made by a licensed provider based on that individual. Your brand offers the doorway. The provider decides what is appropriate, including whether anything is.

What changed when the shortages ended

For a period, FDA drug shortage listings for the major GLP-1 molecules gave compounders broader room to prepare versions of those drugs. When the FDA determined those shortages were resolved, that room narrowed significantly. Federal law generally restricts compounding what is essentially a copy of a commercially available approved drug, and compounding that does proceed depends on patient-specific prescriptions and the prescriber's individual clinical judgment.

Rules, FDA enforcement priorities, and litigation in this area keep evolving, and state boards of pharmacy add their own requirements. So the compounded pathway for any brand depends on current law, on what your licensed pharmacy partners can lawfully prepare, and on the prescriber's patient-specific judgment. Confirm the current position with your pharmacy partner and healthcare counsel before launch, and again whenever the landscape moves. Build your catalog and your messaging so the compounded lane can narrow without breaking the brand.

Checklist: the clinical layer

A provider network licensed in every state you serve, with weight management protocols those providers have signed off on. You do not need to be a clinician to own the business. Under a management services (MSO) model, licensed providers make all prescribing decisions.

An intake that screens properly. Medical history, current medications, and known contraindications should reach the provider before any prescription decision. Some applicants will not qualify, and that is how it should work.

Labs and follow-up. Where a provider's protocol calls for lab work, at-home labs should be wired into intake and follow-up rather than handled as a manual side task. Scheduled check-ins, dose decisions made by the provider, and a clear route for patients to reach their care team are part of the product.

Licensed pharmacy partners for each pathway you offer, plus shipping that handles temperature-sensitive products correctly.

A support model with clinical routing. Patients will have questions about side effects, shipments, and billing. Operational questions go to customer support; clinical questions go to a provider; anything urgent is directed to emergency care. Write those rules down before launch, and make sure your chat and SMS tools follow them.

Checklist: the compliance layer

Claims discipline. Never describe compounded products as FDA approved or generic. No weight-loss promises, no specific results, no before-and-after imagery that ad platforms prohibit. Talk about the care model, the provider review, and the process instead.

LegitScript certification, which major ad platforms and many payment processors require. GrowPro files through its LegitScript Enterprise account, and the certification is issued to the founder's company.

Subscription billing and cancellation that meets federal and state automatic-renewal rules: clear disclosure of recurring charges, affirmative consent, and an easy way to cancel. Weight management is subscription-heavy, so this matters more here than almost anywhere.

Privacy. HIPAA-aligned handling of patient data, business associate agreements with vendors, and no health information flowing into ad pixels. Add A2P-registered SMS and telehealth-underwritten merchant processing and the compliance foundation is in place.

How a new GLP-1 brand actually competes

Pair weight management with other verticals. A patient who arrives for weight management may also be navigating hormones, energy, skin and hair changes, or simply wants better data on her health. A brand that can offer HRT, TRT, labs, wearables, and skin and hair care, each subject to provider judgment, has more than one reason for that patient to stay, and more than one way to reach her in the first place.

Lead with symptoms, not molecules. Creative that speaks to how people feel and what they are struggling with competes in less crowded auctions than creative that leads with drug names, and it is easier to keep compliant.

Retention is clinical. Real follow-up, labs where protocols call for them, and a responsive care team are what keep a subscription relationship healthy. Discounting at the front door is not a retention strategy.

How GrowPro builds it with you

GrowPro is a done-for-you telehealth brand launch, built WITH the founder: brand, compliant website, WellieMD platform configuration, CRM and SMS, merchant processing in your name, LegitScript filed through our Enterprise account with the certification issued to your company, provider and pharmacy network activation with licensed 503A and 503B pharmacies, at-home labs and wearables integration, test orders, QA, launch, and 30 days of post-launch support.

A standard build runs 8 to 12 weeks, and we have launched 80+ brands. GLP-1, Branded Medication, HRT, TRT, labs, wearables, and skin and hair are all in the base build, so you are not launching a one-lane brand. We take 0% revenue share and 0% equity, and our founder runs her own brands on the same infrastructure.

GrowPro brands run on the WellieMD telehealth platform, which connects intake, licensed providers, pharmacy partners, labs, and subscriptions in one system.